Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Pharmaceutical R&D expenditure by therapeutic area Worldwide 2015

Share of pharmaceutical research and development expenditure Worldwide in 2015, by therapeutic area

by Statista Research Department, last edited Dec 20, 2016
Pharmaceutical R&D expenditure by therapeutic area Worldwide 2015 This statistic presents the share of pharmaceutical R&D expenditure worldwide in 2015, by therapeutic area. R&D expenditure on anti-cancer and immunomodulators accounts for 28 percent, R&D expenditure on alimentary and metabolism accounts for 10.4 percent.
Show more

Share of pharmaceutical research and development expenditure Worldwide in 2015, by therapeutic area

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Global pharmaceutical industry"
  • Overview
The most important statistics
  • Companies and products
  • Top companies by revenue
  • R&D, patents, new products
  • Outlook
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.